Collaborative Development and License Agreement Sample Contracts
COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA PHARMACEUTICALS, INC. and ABBOTT LABORATORIES November 27, 2006 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote...Collaborative Development and License Agreement • February 9th, 2016 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [●], 20 , by and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”).
Standard Contracts
COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • November 4th, 2016 • Immunogen Inc • Pharmaceutical preparations • New York
This COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of July 7, 2006 (the “Effective Date”), by and between ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 128 Sidney Street, Cambridge, Massachusetts, USA 02139 (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstraße 5, D-63303 Dreieich, Germany (“Biotest”). Each of Biotest and ImmunoGen is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
THIRD AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • February 5th, 2021 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Third Amendment”) is entered into as of October 20, 2014, by and between Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”) and AbbVie Inc., having a place of business at 1 North Waukegan Road, North Chicago, Illinois 60064 (“AbbVie”). AbbVie and Enanta are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA PHARMACEUTICALS, INC. and ABBOTT LABORATORIES November 27, 2006Collaborative Development and License Agreement • February 5th, 2021 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [ ● ], 20___, by and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”).
FOURTH AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • May 8th, 2015 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations
This FOURTH AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Fourth Amendment”) is entered into as of March 3, 2015, by and between Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”), and AbbVie Inc., having a place of business at 1 North Waukegan Road, North Chicago, Illinois 60064 (“AbbVie”). AbbVie and Enanta are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 2 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • February 5th, 2015 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 2 (this “Amendment No. 2”) to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the “Agreement Effective Date”), as amended as of August 23, 2006 (the “Agreement”) by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landerstrasse 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of December10, 2014.
AMENDMENT NO. 3 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • November 9th, 2017 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 3 (this “Amendment No. 3”) to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the “Agreement Effective Date”), as amended as of August 23, 2006 and December 10, 2014 (the “Agreement”) by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstrasse 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of October 26, 2017.
AMENDMENT NO. 1 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • November 3rd, 2006 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 1 (this "Amendment No. 1") to the Collaborative Development and License Agreement (this “Agreement”) entered into as of July 7, 2006 (the "Agreement Effective Date") by and between ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 128 Sidney Street, Cambridge, Massachusetts, USA 02139 (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstraße 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of August 23, 2006 (the “Amendment Effective Date”).
AMENDMENT AND AGREEMENTCollaborative Development and License Agreement • March 14th, 2005 • Nektar Therapeutics • Pharmaceutical preparations • New York
This Amendment and Agreement is made and entered into as of October 9, 1998 by and between INHALE THERAPEUTIC SYSTEMS, INC., a Delaware corporation (“INHALE”), and PFIZER INC., a Delaware corporation (“PFIZER”).
COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT BETWEEN INHALE THERAPEUTIC SYSTEMS AND PFIZER INC. January 18, 1995Collaborative Development and License Agreement • March 14th, 2005 • Nektar Therapeutics • Pharmaceutical preparations • New York
This Agreement is made and entered into 18 January 1995 and is effective as of the Effective Date (as defined in Section 17.1) by and between INHALE THERAPEUTIC SYSTEMS, a California corporation (“INHALE”), and PFIZER INC., a Delaware corporation (“PFIZER”). INHALE and PFIZER are sometimes referred to herein individually as a “Party” and collectively as the “Parties”, and references to “INHALE” and “PFIZER” shall include their respective Affiliates.
AMENDMENT TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • March 14th, 2005 • Nektar Therapeutics • Pharmaceutical preparations • New York
This Amendment is made and entered into as of September 27,1996 by and between INHALE THERAPEUTIC SYSTEMS, a California corporation (“INHALE”) and PFIZER INC., a Delaware corporation (“PFIZER”).
Incorporated by ReferenceCollaborative Development and License Agreement • January 11th, 2018
Exhibit Number Exhibit Description Form Date Exhibit Number File Number Filed Herewith 10.4† Collaborative Development and License 10-Q 02/09/2016 10.1 001-35839 Agreement between the Company and Abbott Laboratories, dated November 27, 2006; as amended by a First Amendment to Collaborative Development and License Agreement dated January 27, 2009 and a Second Amendment to Collaborative Development and License Agreement dated December 9, 2009 (assigned to AbbVie Inc. as of January 1, 2013). 10.5† Third Amendment to Collaborative Development 10-K 12/11/2014 10.5 001-35839 and License Agreement between the Company and AbbVie dated October 20, 2014. 10.6 Fourth Amendment to Collaborative Development 10-Q 05/08/2015 10.1 001-35839 and License Agreement between the Company and AbbVie dated as of March 3, 2015. 10.7 Lease Agreement between Co
Enanta has requested that portions of this document be accorded confidential treatment pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended. THIRD AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENTCollaborative Development and License Agreement • December 11th, 2014 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO THE COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Third Amendment”) is entered into as of October 20, 2014, by and between Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”) and AbbVie Inc., having a place of business at 1 North Waukegan Road, North Chicago, Illinois 60064 (“AbbVie”). AbbVie and Enanta are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
XENON PHARMACEUTICALS INC. and IVAX INTERNATIONAL GMBH COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT Effective as of December 7, 2012Collaborative Development and License Agreement • October 6th, 2014 • Xenon Pharmaceuticals Inc. • Pharmaceutical preparations • Ontario
XENON PHARMACEUTICALS INC., a Canadian corporation having its principal place of business at 3650 Gilmore Way, Burnaby, British Columbia, V5G 4W8 (“Xenon”)
